ReportAlert.info - Novo Nordisk (CPH:NOVO.B) Publishes 2011 Annual Report
The Company has published its 8th integrated annual report with strong financial, social and environmental performance for 2011
(3BL Media / theCSRfeed) February 10, 2012 - Novo Nordisk reports strong financial, social and environmental results in 8th integrated annual report
BAGSVÆRD, Denmark, 7 February 2012 - Novo Nordisk has published its 8th integrated annual report with strong financial, social and environmental performance for 2011. Download the report here.
The company’s 2011 achievements include:
• Increased sales by 11% (in local currencies) and by 9% in Danish kroner compared to 2010.
• Increased operating profit by 22% (in local currencies) and 18% in Danish kroner compared to 2010.
• Filed for regulatory approval for marketing authorization of two new ultra-long-acting insulins, Degludec and DegludecPlus, in major markets.
• Reached an estimated 24 million people with injectable diabetes care products during 2011.
• Educated or trained more than 835,000 healthcare providers to improve diabetes care.
• Reduced CO2 emissions from production by 2% compared to 2010, achieving an absolute reduction of 56% compared to 2004.
Novo Nordisk’s Annual Report 2011 provides details about the company’s strong sales growth, good performance against long-term financial, social and environmental targets and very significant progress in its clinical development pipeline. The company’s report includes an outlook for 2012 performance, an overview of the company’s management approach, strategy and therapy areas, and consolidated financial, social and environmental statements.
While Novo Nordisk’s Annual Report 2011 includes important performance, strategic and governance information, as well as details on issues deemed material to the company’s business, additional information of interest to specific stakeholder groups can be found on its Annual Report 2011 website.
As an experienced integrated reporter and a part of the International Integrated Report Committee (IIRC) pilot programme, the company’s 2011 reporting includes information reported in reference to the International Integrated Report Framework.
About Novo Nordisk
Novo Nordisk is a global healthcare company with nearly 90 years of innovation and leadership in diabetes care. The company also has leading positions within haemophilia care, growth hormone therapy and hormone replacement therapy. For more information, visit novonordisk.com
CR21026
